carthera.eu

Webside score carthera.eu

Home - Carthera

 Genereret April 09 2026 01:59 AM

Gammel data? OPDATER !

Scoren er 61/100

SEO Indhold

Titel

Home - Carthera

Længde : 15

Perfekt, din titel indeholder mellem 10 og 70 bogstaver.

Beskrivelse

Revolutionizing severe brain disease treatments

Længde : 47

Kan optimeres; din meta beskrivelse bør indeholde mellem 70 og 160 karakterer (med mellemrum). Brug dette gratis redskab til at regne længden ud.

Nøgleord

Dårligt! Vi kan ikke finde nogle meta nøgleord på din side! Brug denne gratis online meta generator for at oprette nye nøgleord.

Og Meta Egenskaber

Godt, din side benytter Og egenskaberne

Egenskab Indhold
locale en_US
locale:alternate fr_FR
type website
title Home - Carthera
description Revolutionizing severe brain disease treatments
url https://carthera.eu/
site_name Carthera

Overskrifter

H1 H2 H3 H4 H5 H6
1 5 73 0 0 0
  • [H1] GLIOBLASTOMA and CNS DISEASES Revolutionizingbrain treatments
  • [H2] CARTHERA In a few figures
  • [H2] NO BRAIN DISEASE beyond reach
  • [H2] CLINICAL NEED AND SOLUTION Overcoming the BBB
  • [H2] Our latest news
  • [H2] AGENDA Our events
  • [H3] Our team
  • [H3] Indications
  • [H3] Strategy
  • [H3] Our ambition
  • [H3] Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel
  • [H3] Repeated blood−brain barrier opening using low-intensity pulsed ultrasound mitigates amyloid pathology
  • [H3] Carthera receives EMA expert panel endorsement for Orphan Medical Device status of SonoCloud® system
  • [H3] Carthera reaches recruitment milestone in SONOBIRD pivotal trial for recurrent glioblastoma
  • [H3] Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening
  • [H3] Effects of blood-brain barrier opening using ultrasound on tauopathies: A systematic review
  • [H3] Using ultrasound technology to open the blood brain barrier
  • [H3] Endothelial response to blood-brain barrier disruption in the human brain
  • [H3] Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound- mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas
  • [H3] Effect of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an ALS mouse model
  • [H3] Carthera receives positive opinion from French High Authority for Health on Innovation Funding scheme to treat patients with recurrent glioblastoma
  • [H3] Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas
  • [H3] Carthera receives Orphan Drug Designation (ODD) from US and EU authorities for carboplatin in malignant glioma
  • [H3] Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma
  • [H3] Carthera partners with Agenus and Northwestern University for phase 2a trial combining SonoCloud-9® with checkpoint inhibitors to treat glioblastoma
  • [H3] Positive results from phase I/II clinical trial of SonoCloud-9® in treatment of glioblastoma published in Nature Communications
  • [H3] Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial
  • [H3] Carthera enrolls first patient in pivotal trial of SonoCloud-9® device for treatment of recurrent glioblastoma
  • [H3] Series B round reaches €42M
  • [H3] Carthera signs strategic collaboration with Accord Healthcare
  • [H3] Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase I clinical trial
  • [H3] Evaluating drug delivery enhancement following ultrasound treatment
  • [H3] Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas
  • [H3] Carthera appoints Dr. Oern Stuge as chairman of board of directors
  • [H3] Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials
  • [H3] Low-Intensity Pulsed Ultrasound-Mediated Blood-Brain Barrier Opening Increases Anti-Programmed Death-Ligand 1 Delivery and Efficacy in Gl261 Mouse Model
  • [H3] Carthera closes €37.5M Series B funding round
  • [H3] Promising results from SonoCloud-9 clinical trial in combination with nab-paclitaxel have been published in Lancet Oncology
  • [H3] Carthera announces positive outcome of End-of-Phase 2 meeting with FDA for SonoCloud-9 system for treatment of recurrent glioblastoma
  • [H3] Carthera receives FDA Breakthrough Device Designation for SonoCloud-9 system
  • [H3] Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease
  • [H3] Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
  • [H3] SonoCloud® technology enhances the efficacy of immunotherapies for the treatment of brain tumor.
  • [H3] Launch of a new phase I/IIclinical trial in collaboration with Northwestern University in Chicago
  • [H3] Carthera receive €2M grant and €10.5M equity from the European Innovation Council
  • [H3] First patient enrolled in new clinical trial for SonoCloud technology in melanoma
  • [H3] Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors
  • [H3] Blood–brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors
  • [H3] Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations
  • [H3] Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives
  • [H3] Study of the means to characterize the opening of the blood-brain barrier induced by an implantable ultrasound device
  • [H3] Strategic collaboration with US-based company Lantheus
  • [H3] Latest data from the SonoCloud-9 clinical study presented at SNO on November 20-24, 2019
  • [H3] Collaboration with KIYATEC in effort to bring personalized medicine to patients stricken by brain cancer
  • [H3] FDA approval to launch a Phase 1/2a trial in glioblastoma
  • [H3] Pascal Girin, new chairman of the Board of Directors
  • [H3] Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma
  • [H3] Publishing of complete results of Phase I/IIa clinical trial using the SonoCloud-1 ultrasound implant
  • [H3] Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma
  • [H3] Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure
  • [H3] ANSM approval to launch a phase I-II clinical trial for the SonoCloud-9 device
  • [H3] Closing of a €9M ($10.3M) Series B funding round
  • [H3] Potentialisation des chimiothérapies dans le traitement du glioblastome : étude des transporteurs ABC et ouverture de la barrière hémato-encéphalique par ultrasons
  • [H3] Capacitive Micro-machined Ultrasound Transducers for Interstitial High Intensity Ultrasound Therapies
  • [H3] Blood-brain barrier, cytotoxic chemotherapies and glioblastoma
  • [H3] Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate mod
  • [H3] Clinical trial of blood-brain barrier disruptionby pulsed ultrasound
  • [H3] Enhanced brain distribution ofcarboplatin ina primate model afterblood–brain barrier disruption using an implantable ultrasound device
  • [H3] Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits
  • [H3] A multi-element interstitial ultrasound applicator for the thermaltherapy of brain tumors
  • [H3] Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits
  • [H3] 30th Annual Meeting of SNO, Society for Neuro-Oncology
  • [H3] 20th Annual Meeting of EANO, European Association of Neuro-Oncology
  • [H3] Congress of Neurological Surgeons (CNS)
  • [H3] Annual Congress of EANS, European Association of Neurosurgical societies
  • [H3] 24th Annual International Symposium on Therapeutic Ultrasound (ISTU)
  • [H3] Annual meeting of ANOCEF, Association des Neuro-oncologues d'Expression Française
  • [H3] Brain Tumor Biotech Day
  • [H3] NMN symposium, Nuclear medecine and Neuro-Oncology

Billeder

Vi fandt 102 billeder på denne side.

71 alt tags mangler eller er tomme. Tilføj alternativ tekst til dine billeder for at gøre siden mere brugervenlig, og for at optimere din SEO i forhold til søgemaskinerne.

Text/HTML balance

Balance : 31%

Optimalt! Denne sides text til HTML fordeling er mellem 25 og 70 procent.

Flash

Perfekt, ingen Flash objekter er blevet fundet på siden.

iFrame

Beklager! Din side har iFrames og det kan medføre i yderst dårlig læsning af søgerobotterne.

URL Omskrivning

Godt. Dine links ser venlige ud!

Underscores i links

Perfekt! Ingen underscores blev fundet i dine links

On-page links

Vi fandt et total af 10 links inkluderende 0 link(s) til filer

Anker Type Juice
About Us Intern Sender Juice
Our Solutions Intern Sender Juice
Research & Development Intern Sender Juice
Our News Intern Sender Juice
Legal Mentions & Disclaimer Intern Sender Juice
Privacy Policy Intern Sender Juice
U.S. Expanded Access Policy Intern Sender Juice
Sitemap Intern Sender Juice
Contact (EN) Intern Sender Juice
Kookline Ekstern Sender Juice

SEO Nøgleord

Nøgleords cloud

read scientific ultrasound brain request glioblastoma barrier publication more carthera

Nøgleords balance

Nøgleord Indhold Titel Nøgleord Beskrivelse Overskrifter
publication 69
scientific 34
carthera 32
request 32
brain 32

Brugervenlighed

Link

Domæne : carthera.eu

Længde : 11

FavIkon

Godt, din side har et FavIcon!

Printervenlighed

Vi kunne ikke finde en printer venlig CSS skabelon.

Sprog

Godt, dit tildelte sprog er en.

Dublin Core

Denne side benytter IKKE Dublin Core principperne.

Dokument

Dokumenttype

HTML 5

Kryptering

Perfekt. Dit Charset er tildelt UTF-8.

W3C Validering

Fejl : 0

Advarsler : 0

Email Privatliv

Advarsel! Mindst én email adresse er blevet fundet i rå tekst. Brug gratis antispam beskytter for at hemme din email fra spammere.

Udgået HTML

Godt! Vi har ikke fundet udgåede HTML tags i din kildekode

Hastigheds Tips

Alle tiders! Din webside bruger ikke nestede tabeller.
Advarsel! Din webside benytter inline CSS kode!
Godt, din website har få antal CSS filer
Perfekt, din website har få JavaScript filer.
Perfekt, din hjemmeside udnytter gzip.

Mobil

Mobil Optimering

Apple Ikon
Meta Viewport Tag
Flash indhold

Optimering

XML Sitemap

Stor, din hjemmeside har en XML sitemap.

https://carthera.eu/sitemap_index.xml

Robots.txt

https://carthera.eu/robots.txt

Stor, din hjemmeside har en robots.txt-fil.

Analytics

Mangler

Vi har ikke registrerer en analyseværktøj installeret på denne hjemmeside.

Web analytics kan du måle besøgendes aktivitet på dit websted. Du bør have mindst én analyseværktøj installeret, men det kan også være godt at installere et sekund for at krydstjekke data.

PageSpeed Insights

Apparat
Kategorier

Free SEO Testing Tool

Free SEO Testing Tool er et gratis SEO redskab der hjælper med din hjemmeside